Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity

American Journal of Medicine

Volumn 123, Issue 12, 2010, Pages 1143-1149

  Pritchard, Lindsey ^a   Baker, Catherine ^b   Leggett, James ^c   Sehdev, Paul ^b   Brown, Allen ^d   Bayley, K Bruce ^c  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^c PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^d Providence Health Plans   (United States)

Author keywords

Nephrotoxicity; Serum concentrations; Trough; Vancomycin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VANCOMYCIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; INDEPENDENT VARIABLE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NEPHROTOXICITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; TREATMENT DURATION;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CREATININE; FEMALE; HUMANS; INCIDENCE; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN;

EID: 78650449850     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.07.025     Document Type: Article

References (22)

1. M. Rybak, B. Lomaestro, and J.C. Rotshafer Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
2. A.R. Tunkel, B.J. Hartman, and S.L. Kaplan Practice guidelines for the management of bacterial meningitis Clin Infect Dis 39 2004 1267 1284
3. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
4. P.A. Moise, G. Sakoulas, A. Forrest, and J.J. Schentag Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia Antimicrob Agents Chemother 51 2007 2582 2586
5. M.N. Jeffres, W. Isakow, and J.A. Doherty Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices Chest 130 2006 947 955
6. W.J. Youden An index for rating diagnostic tests Cancer 3 1950 32 35
7. G.H. Dunteman Principal components analysis Sage University Paper series on Quantitative Applications in the Social Sciences, series no. 07-069 1989 Sage Newbury Park, CA
8. A.H. Thomson, C.E. Staatz, and C.M. Tobin Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations J Antimicrob Chemother 63 2009 1050 1057
9. T.G. Cantu, N.A. Yamanaka-Yuen, and P.S. Lietman Serum vancomycin concentrations: reappraisal of their clinical value Clin Infect Dis. 18 1994 533 543
10. K. Kralovicova, S. Spanik, and J. Halko Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients? J Chemother 9 1997 420 426
11. A.E. Zimmermann, B.G. Katona, and K.I. Plaisance Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia Pharmacotherapy 15 1995 85 91
12. L.K. Hidayat, D.I. Hsu, and R. Quist High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity Arch Intern Med 166 2006 2138 2144
13. M.N. Jeffres, W. Isakow, and J.A. Doherty A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia Clin Ther 29 2007 1107 1115
14. M.J. Rybak, L.M. Albrecht, S.C. Boike, and P.H. Chandrasekar Nephrotoxicity of vancomycin, alone and with an aminoglycoside J Antimicrob Chemother 25 1990 679 687
15. T.P. Lodise, B. Lomaestro, J. Graves, and G.L. Drusano Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity Antimicrob Agents Chemother 52 2008 1330 1336
16. T.P. Lodise, N. Patel, and B. Lomaestro Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients Clin Infect Dis 49 2009 507 514
17. N. Pannu, and M.K. Nadim An overview of drug-induced acute kidney injury Crit Care Med 36 4 suppl 2008 S216 S223
18. N.J. Downs, R.E. Neihart, J.M. Dolezal, and G.R. Hodges Mild nephrotoxicity associated with vancomycin use Arch Intern Med 149 1989 1777 1781
19. B.F. Farber, and R.C. Moellering Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 Antimicrob Agents Chemother 23 1983 138 141
20. T.P. Lodise, J. Graves, and A. Evans Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin Antimicrob Agents Chemother 52 2008 3315 3320
21. M.H. Kollef, L.M. Napolitano, and J.S. Solomkin Health careassociated infection (HAI): a critical appraisal of the emerging threatproceedings of the HAI Summit Clin Infect Dis 47 2 suppl 2008 S55 S99
22. K.A. Hazlewood, S.D. Brouse, W.D. Pitcher, and R.G. Hall Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 123 2010 182.e1 182.e7